9 / 40
Resultados:
Biopsia liquida basales
•
When a MAF of ≥ 0.02% was used, negative % agreement between solid
and liquid biopsies was 87.4%
Exon
Mutant allele fraction (cut-off)
≥ 1%
≥ 0.1%
≥ 0.02%
KRAS
mutated, n (%)
2
3 (2.5)
5 (4.2)
11 (9.2)
3
0 (0)
0 (0)
0 (0)
4
0 (0)
0 (0)
1 (0.8)
Total
3 (2.5)
5 (4.2)
12 (10.1)
NRAS
mutated, n (%)
2
0 (0)
1 (0.8)
2 (1.7)
3
0 (0)
1 (0.8)
2 (1.7)
Total
0 (0)
2 (1.7)
4 (3.4)
Detection rate for
RAS
mutated,
% (95% CI)*
2.5 (0.5 – 7.2)
5.0 (1.9 – 10.7)
12.6 (7.2 – 19.9)
Negative % agreement**, %
(95% CI)
97.5 (92.8 –
99.5)
95.0 (89.4 – 98.1)
87.4 (80.1 – 92.8)
*One patient had both
KRAS
and
NRAS
mutations
**Percentage concordance in patients with wild-type
RAS
according to solid biopsy
Valladares et al. SEOM congress 2018; Abstract O-39 (and oral presentation)
García-Alfonso et al. ESMO congress 2018; Abstract 3887 (and poster discussion)
Discordant Patients (n= 15).
Most patients with plasma RAS mutations and a
low MAF had a response (partial or complete) with panitumumab